EGF and cancer: For interfering of RAS-effector interaction through binding of a small molecule to effector protein, rigosertib was reported (Table 3) which binds to the RAS-binding domain (RBD) of RAS effectors preventing their interaction with activated RAS in cancer cells; regardless, it is activated by mutations of RAS proteins, or it is induced by epidermal growth factor (EGF) [76].